A Phase IIb/III Trial of ApoCell in Graft versus Host Disease

Trial Profile

A Phase IIb/III Trial of ApoCell in Graft versus Host Disease

Planning
Phase of Trial: Phase II/III

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Enlivex Therapeutics
  • Most Recent Events

    • 28 Jan 2015 New trial record
    • 26 Jan 2015 According to Enlivex Therapeutics media release, ApoCell has received orphan drug status in US and European union.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top